Seattle-based privately held Nohla Therapeutics Inc. completed a $45 million series B financing from certain investors, which included Celgene Corp.
Nohla develops off-the-shelf cell therapies for treating cancer and other critical diseases.
The particular round of financing also included Fidelity Management and Research Co., ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners.
Nohla intends to use the proceeds to complete ongoing phase 2 trials of its lead product candidate dilanubicel, a stem and progenitor cell therapy designed to provide short-term bone marrow function, to support commercial manufacturing needs and advance its product pipeline.
